Life sciences company Bionano Genomics (NASDAQ:BNGO) shares aren’t as cheap vis-à-vis 2020. But the recent pullback, the Genomics company is alluring despite the risks involved. A believer in Genomics mapping technology may feel that the firm is solid for a small capital position.
Closer examination of the company should disclose much promise- financially as well as clinically. The company shares rallied in December from 50 cents and reached a 52-week high of $15.69 in February 2021. When a stock surges by 3000%, it is wise to sell your shares. The company shares pulled back and in August are at $5.92.
This reflects an opportunity to accumulate the stock as revisiting $10 will be a reasonable target for the Genomic company share. The company has multiple products but its best-known or Saphyr system, a genome imaging tool for high-speed as well as structural variant detection and analysis. The conditions that can be detected rapidly include cancers as well as developmental orders and the system reveals at sensitivities as high as 99%, with false-positive rates below 2%.
Results from research at the University Hospitals Leuven, Belgium confirmed it to be the gold standard of optical genome mapping tools. An assay was done for complete genome analysis of 40 acute lymphoblastic leukemia subjects. Additionally, improved outcomes were established with 5% cases demonstrating improvement in treatment from enhanced prognostic stratification.